Yumanity Therapeutics to Present at the 2021 B. Riley Securities’ Neuroscience Conference

Rhea-AI Summary

Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, announced that Richard Peters, M.D., Ph.D., will present at the 2021 B. Riley Securities’ Neuroscience Conference. The presentation will be available on-demand starting April 29, 2021, at 2:30 p.m. EDT via the conference portal and the company’s website.

Yumanity’s lead candidate, YTX-7739, is in Phase 1 development for Parkinson’s disease. The company also has programs targeting Lewy body dementia, ALS, FTLD, and Alzheimer’s disease.

BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the 2021 B. Riley Securities’ Neuroscience Conference.

The presentation will be available on-demand via the conference portal and through the Company's website at www.yumanity.com/events beginning at 2:30 p.m. EDT, April 29.

About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com.

Investors:
Burns McClellan, Inc.
Lee Roth
lroth@burnsmc.com
(212) 213-0006

Media:
Burns McClellan, Inc.
Ryo Imai / Robert Flamm, Ph.D.
rimai@burnsmc.com / rflamm@burnsmc.com
(212) 213-0006

FAQ

When will Yumanity Therapeutics present at the 2021 Neuroscience Conference?

Yumanity Therapeutics will present at the 2021 B. Riley Securities’ Neuroscience Conference on April 29, 2021, at 2:30 p.m. EDT.

Where can I watch Yumanity Therapeutics' presentation?

The presentation will be available on-demand via the conference portal and on Yumanity Therapeutics' website.

What is Yumanity Therapeutics' lead product candidate?

Yumanity Therapeutics' lead product candidate is YTX-7739, which is currently in Phase 1 clinical development for Parkinson's disease.

What diseases does Yumanity Therapeutics focus on?

Yumanity Therapeutics focuses on neurodegenerative diseases, including Parkinson's disease, Lewy body dementia, ALS, FTLD, and Alzheimer's disease.

What is the significance of the Neuroscience Conference for Yumanity Therapeutics?

The Neuroscience Conference provides a platform for Yumanity Therapeutics to showcase its innovative therapies and advancement in treating neurodegenerative diseases.